Vrielynck P, Marique P, Ghariani S, Lienard F, de Borchgrave V, van Rijckevorsel K, Bonnier C
William Lennox Neurological Hospital, Reference Center for Refractory Epilepsy, Université Catholique de Louvain, Ottignies, Belgium.
William Lennox Neurological Hospital, Reference Center for Refractory Epilepsy, Université Catholique de Louvain, Ottignies, Belgium.
Eur J Paediatr Neurol. 2017 Mar;21(2):305-311. doi: 10.1016/j.ejpn.2016.08.015. Epub 2016 Sep 8.
Encephalopathy with continuous spike-wave during sleep (CSWS) is a particularly difficult-to-treat childhood epileptic syndrome. This study sought to present the EEG improvement and clinical efficacy of topiramate (TPM), a broad spectrum antiepileptic drug (AED), in a series of 21 children with CSWS encephalopathy.
We retrospectively reviewed the EEG results and clinical data of children with CSWS followed-up in our institution and treated with TPM. Sleep EEGs were performed 0-3 months prior to TPM introduction and then at 3 and 12 months. The exclusion criteria were (1) introduction of another AED and (2) withdrawal of a potentially aggravating AED during the first 3 months of treatment. In addition to spike index (SI), the severity of EEG abnormalities was rated using an original scale that also considered the spatial extent of interictal epileptiform discharges.
21 patients were included (18 males, 4-14y, three symptomatic cases). At 3 months, sleep EEG was improved in 14 and normalized in four (TPM doses: 2-5.5 mg/kg/day). Among these 18 patients, 16 manifested cognitive or behavioural improvement. In a subgroup of seven patients with frequent seizures, five became seizure-free and one had over 75% decrease in seizure frequency. At the one-year follow-up, 20 children were still on TPM and 10 exhibited persistent EEG improvement without any other AED being introduced, most of them with clinical benefits.
TPM can decrease EEG abnormalities in epileptic encephalopathy with CSWS, achieving clinical improvement in the majority of patients. However, relapse may occur in the long-term in nearly half of cases. Otherwise, TPM has proven particularly useful in reducing seizure frequency in refractory cases.
睡眠期持续性棘慢波癫痫(CSWS)是一种治疗难度特别大的儿童癫痫综合征。本研究旨在呈现托吡酯(TPM),一种广谱抗癫痫药物(AED),对21例CSWS脑病患儿的脑电图改善情况及临床疗效。
我们回顾性分析了在本机构接受随访并接受TPM治疗的CSWS患儿的脑电图结果和临床资料。在引入TPM前0 - 3个月、引入后3个月和12个月进行睡眠脑电图检查。排除标准为:(1)引入另一种AED;(2)在治疗的前3个月内停用可能加重病情的AED。除棘波指数(SI)外,还使用一种原始量表对脑电图异常的严重程度进行评估,该量表还考虑了发作间期癫痫样放电的空间范围。
纳入21例患者(18例男性,4 - 14岁,3例症状性病例)。3个月时,14例患者的睡眠脑电图有所改善,4例恢复正常(TPM剂量:2 - 5.5毫克/千克/天)。在这18例患者中,16例表现出认知或行为改善。在7例频繁发作的亚组患者中,5例无发作,1例发作频率降低超过75%。在一年的随访中,20名儿童仍在服用TPM,10名儿童脑电图持续改善,未引入任何其他AED,其中大多数有临床获益。
TPM可减少CSWS癫痫性脑病的脑电图异常,使大多数患者临床症状改善。然而,近一半的病例可能会出现长期复发。此外,TPM已被证明在降低难治性病例的发作频率方面特别有用。